Positive interim safety results from the first two dose escalation cohorts, referred to as Cohorts 1 and 2, were reported in 4Q 2024. Today’s update is focused on safety and molecular findings from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback